Unmet need
Obesity and related metabolic disorders continue to outpace durable, broad-spectrum treatment outcomes.
Metabolic Balance By Design
A stealth-stage biopharma building a science-led bioenergetics thesis around energy expenditure, body composition, and glycemic control for long-term metabolic-health impact.
- Stealth-stage bioenergetics platform
- Calories-out metabolic framing
- Disciplined investor dialogue
Mission overview
Metabolic health still faces a meaningful unmet need beyond intake-focused approaches.
Calo Bio is exploring the energy-balance side of the equation with a focus on outcomes that matter to patients, including glycemic control and body composition over time.
Energy expenditure
Activating calories-out biology may complement appetite-led strategies in future metabolic-care paradigms.
Body composition
Improving fat-quality dynamics may support healthier composition trajectories alongside cardiometabolic markers.
Strategic pillars
Three themes that define Calo Bio’s vision
A high-level framework for how we think about metabolic-health impact, scientific direction, and execution discipline.
Calories-Out Metabolic Vision
We frame long-term metabolic health through energy expenditure and body-composition outcomes, designed to complement appetite-centered care.
Bioenergetic Mechanism Focus
Our thesis explores how brown, beige, and white fat biology may influence glycemic control and durable metabolic balance.
Disciplined Execution
Calo Bio advances a proprietary program with scientific rigor, selective disclosure, and milestone-driven capital discipline.
Scientific thesis
A calories-out framing for metabolic health, presented at a high level.
Calo Bio is exploring a bioenergetics-centered approach designed to complement established appetite pathways.
Calories-out lens
Metabolic health can be influenced by how efficiently the body expends energy, not only by how much energy is consumed.
Beyond appetite-only models
Appetite-focused strategies may not fully address variability in basal and adaptive metabolic rate across patient profiles.
Body composition ambition
The long-term objective is to support fat-loss outcomes while helping preserve lean mass and improve glycemic control.
For additional context, see the investor FAQ or contact the team.
Leadership
Built for long-horizon execution
Calo Bio is being shaped by operators and scientists with disciplined development judgment, translational rigor, and a clear focus on building durable value in metabolic health.
Nader Daoud
CO-FOUNDER & PRESIDENT
Nader Daoud drives corporate strategy, capital formation, and enterprise growth at Calo Bio. He charts Calo's path to patients, converting frontier bioenergetics into metabolic therapeutics reshaping human health. Before Calo, he spent more than a decade in clinical development and operations at Moderna, Takeda, and Mass General Brigham, leading cross-functional teams and multimillion-dollar global programs across liver, kidney, cardiovascular, and rare diseases.
Nicole DelGaudio
CO-FOUNDER & CHIEF SCIENTIFIC OFFICER
Nicole DelGaudio is a PhD candidate at The Rockefeller University with expertise in mitochondrial metabolism, therapeutic target identification and validation, and preclinical disease models. With a first-author publication in Cancer Discovery and additional work published in Cell Metabolism and Blood, she brings experience translating mechanistic discoveries toward therapeutic opportunities to Calo Bio.
Raquelle Yu
CO-FOUNDER & CHIEF TECHNOLOGY OFFICER
Raquelle Yu is a PhD candidate at Rockefeller University and a metabolism researcher focused on adipose-tissue biology, energy expenditure, and body composition. She leads both scientific direction and company execution with a mechanism-first, capital-disciplined approach to building durable value in metabolic health.
Nicolas Gomez-Banoy, MD, PhD
SCIENTIFIC FOUNDER & CHIEF MEDICAL ADVISOR
Dr. Gomez-Banoy is a physician-scientist with a longstanding interest in understanding the pathophysiology of cardiometabolic diseases and treating patients affected by these conditions. He currently serves as an endocrinology fellow at Weill Cornell and MSKCC, as well as a researcher in the Paul Cohen lab at Rockefeller University. His main interests lie in adipose tissue and its connections to the pathophysiology of diabetes, hypertension, and cancer.
Investor FAQ
Common questions
Calo Bio is intentionally selective about public detail while in stealth. The answers below clarify what we can share now and how to continue a fit-aligned conversation.
What is Calo Bio focused on?
We are a stealth-stage biopharma company exploring a proprietary bioenergetics compound aimed at energy expenditure and body composition in metabolic health.
Why does this opportunity matter now?
Metabolic disease remains a major global burden. We see long-term potential in calories-out mechanisms that may complement appetite-led approaches and broaden future treatment options.
Why are technical details limited publicly?
As a stealth startup, we share only non-confidential information in public channels. This protects scientific work in progress and keeps external communication accurate and responsible.
How can I request follow-up information?
Use the contact pathway below to share your background and area of interest. If there is strategic fit, we will follow up directly with appropriate next steps.
What conversations is the team open to today?
We welcome discussions with early investors, strategic partners, and domain experts aligned with rigorous science, disciplined execution, and long-term metabolic-health impact.
For fit-aligned conversations, please contact the team directly.
Start a focused conversation
We welcome thoughtful dialogue with investors and strategic partners aligned with our long-term bioenergetics vision.
Relevant investor and strategic inquiries are encouraged.